Advancing Education on Biosimilars Act of 2019
USA116th CongressHR-4400| House
| Updated: 9/20/2019
Larry Bucshon
Republican Representative
Indiana
Cosponsors (1)
Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Advancing Education on Biosimilars Act of 2019 This bill requires the Department of Health and Human Services (HHS) to maintain a website and undertake other activities to educate health care providers, patients, and caregivers about biological products, biosimilar biological products, and interchangeable biosimilar biological products. Among other activities, HHS must develop or improve continuing education programs that address clinical considerations for biological and related products. Health care providers eligible for the Merit-based Incentive Payment System in Medicare may count completion of such a program as a clinical practice improvement activity.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelHealth programs administration and fundingImmunology and vaccinationLicensing and registrationsMedical educationMedicarePrescription drugs
Advancing Education on Biosimilars Act of 2019
USA116th CongressHR-4400| House
| Updated: 9/20/2019
Advancing Education on Biosimilars Act of 2019 This bill requires the Department of Health and Human Services (HHS) to maintain a website and undertake other activities to educate health care providers, patients, and caregivers about biological products, biosimilar biological products, and interchangeable biosimilar biological products. Among other activities, HHS must develop or improve continuing education programs that address clinical considerations for biological and related products. Health care providers eligible for the Merit-based Incentive Payment System in Medicare may count completion of such a program as a clinical practice improvement activity.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Larry Bucshon
Republican Representative
Indiana
Cosponsors (1)
Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelHealth programs administration and fundingImmunology and vaccinationLicensing and registrationsMedical educationMedicarePrescription drugs